Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
November 12, 2020 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Third Quarter 2020 Total Revenue of $13.7 Million
November 05, 2020 16:01 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net Product Revenue of $10.9 Million in the Third Quarter 2020; a 35% Increase Over the Prior Quarter-- Paratek now Anticipates Full Year 2020 Total Revenue to be...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 02, 2020 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
October 27, 2020 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020
October 21, 2020 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 01, 2020 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million
August 10, 2020 07:30 ET
|
Paratek Pharmaceuticals
-- Paratek Raises Full Year 2020 Revenue Guidance; Total Revenue guidance expected to be Between $78 and $83 Million Driven by Strong NUZYRA Net Revenue -- Company Lowering 2020 R&D and SG&A...
Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences
August 05, 2020 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 03, 2020 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...